Patient clinical characteristics, peripheral blast and eosinophil counts at time of biopsy, blast phenotype, and response to imatinib
| Patient (age [y]/sex) . | Relevant history . | WBC per μL . | Blasts, % . | Eos, % . | Positive flow cytometry markers, BM blasts . | Response to imatinib (duration) . | Other chemotherapy . | Status, cause of death if relevant . |
|---|---|---|---|---|---|---|---|---|
| 1 (72/F) | Aplastic anemia, AML s/p MRD-RIC-BMT | 248 000 | 18.1 | 2.6 | CD33, CD13, CD117, CD34, HLA-DR(dim), MPO(variable), CD56(variable), CD7 | Unresponsive (4 wk) | Decitabine, venetoclax | +3.5 mo since relapse diagnosis |
| 2 (88/M) | Chronic anemia, thrombocytopenia | 120 400 | 8.0 | 0 | CD33, CD13, CD117, CD34, HLA-DR, CD7 | Not given | Follow-up unavailable | Follow-up unavailable |
| 3 (62/F) | CMML (BCR-ABL1 negative) | 216 600 | 5 | 1 | CD33, CD13, CD117, CD34, HLA-DR | Unresponsive (3 wk) | Azacitadine, hydroxyurea | Deceased, 6 mo, SBP |
| 4 (80/M) | Gastric cancer (remote), MGUS, DLBCL (R-CHOP, XRT), MDS/MPN-U | 704 100 | 90 | 0 | CD33, CD13, CD117, CD34, HLA-DR, CD56, CD38 | Unresponsive (20 wk) | None | Deceased, 5 mo, AML progression |
| 5 (85/F) | None | 937 000 | 16 | 1 | CD13, CD33(variable), CD117, CD34, HLA-DR(variable), CD123(dim, variable), CD38(dim, variable), CD7 | Not given | Azacitadine, venetoclax | +1 mo since diagnosis |
| Patient (age [y]/sex) . | Relevant history . | WBC per μL . | Blasts, % . | Eos, % . | Positive flow cytometry markers, BM blasts . | Response to imatinib (duration) . | Other chemotherapy . | Status, cause of death if relevant . |
|---|---|---|---|---|---|---|---|---|
| 1 (72/F) | Aplastic anemia, AML s/p MRD-RIC-BMT | 248 000 | 18.1 | 2.6 | CD33, CD13, CD117, CD34, HLA-DR(dim), MPO(variable), CD56(variable), CD7 | Unresponsive (4 wk) | Decitabine, venetoclax | +3.5 mo since relapse diagnosis |
| 2 (88/M) | Chronic anemia, thrombocytopenia | 120 400 | 8.0 | 0 | CD33, CD13, CD117, CD34, HLA-DR, CD7 | Not given | Follow-up unavailable | Follow-up unavailable |
| 3 (62/F) | CMML (BCR-ABL1 negative) | 216 600 | 5 | 1 | CD33, CD13, CD117, CD34, HLA-DR | Unresponsive (3 wk) | Azacitadine, hydroxyurea | Deceased, 6 mo, SBP |
| 4 (80/M) | Gastric cancer (remote), MGUS, DLBCL (R-CHOP, XRT), MDS/MPN-U | 704 100 | 90 | 0 | CD33, CD13, CD117, CD34, HLA-DR, CD56, CD38 | Unresponsive (20 wk) | None | Deceased, 5 mo, AML progression |
| 5 (85/F) | None | 937 000 | 16 | 1 | CD13, CD33(variable), CD117, CD34, HLA-DR(variable), CD123(dim, variable), CD38(dim, variable), CD7 | Not given | Azacitadine, venetoclax | +1 mo since diagnosis |
White blood cell counts and percentages of blasts and eosinophils are from peripheral blood at the time of diagnosis. No eosinophils were identified on BM aspirates for patients 2, 3, and 5. Patient 1’s BM aspirate was hypocellular and hemodilute. BM aspirate differential was not recorded for patient 4.
CMML, chronic myelomonocytic leukemia; DLBCL, diffuse large B-cell lymphoma; Eos, eosinophils; F, female; M, male; MDS/MPN-U, myelodysplastic syndrome/myeloproliferative neoplasm-unclassified; MGUS, monoclonal gammopathy of uncertain significance; MRD-RIC-BMT, matched related donor reduced-intensity conditioning BM transplant; R-CHOP, chemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone; SBP, spontaneous bacterial peritonitis; s/p, status post; WBC, white blood cell count; XRT, radiation therapy.